1. Home
  2. EOLS vs GNE Comparison

EOLS vs GNE Comparison

Compare EOLS & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EOLS
  • GNE
  • Stock Information
  • Founded
  • EOLS 2012
  • GNE 2011
  • Country
  • EOLS United States
  • GNE United States
  • Employees
  • EOLS N/A
  • GNE N/A
  • Industry
  • EOLS Biotechnology: Pharmaceutical Preparations
  • GNE Power Generation
  • Sector
  • EOLS Health Care
  • GNE Utilities
  • Exchange
  • EOLS Nasdaq
  • GNE Nasdaq
  • Market Cap
  • EOLS 406.9M
  • GNE 419.3M
  • IPO Year
  • EOLS 2018
  • GNE N/A
  • Fundamental
  • Price
  • EOLS $6.50
  • GNE $15.31
  • Analyst Decision
  • EOLS Strong Buy
  • GNE
  • Analyst Count
  • EOLS 4
  • GNE 0
  • Target Price
  • EOLS $21.25
  • GNE N/A
  • AVG Volume (30 Days)
  • EOLS 1.0M
  • GNE 166.6K
  • Earning Date
  • EOLS 11-05-2025
  • GNE 11-05-2025
  • Dividend Yield
  • EOLS N/A
  • GNE 1.96%
  • EPS Growth
  • EOLS N/A
  • GNE 4.51
  • EPS
  • EOLS N/A
  • GNE 0.31
  • Revenue
  • EOLS $277,941,000.00
  • GNE $456,876,000.00
  • Revenue This Year
  • EOLS $13.68
  • GNE $14.60
  • Revenue Next Year
  • EOLS $27.96
  • GNE $8.64
  • P/E Ratio
  • EOLS N/A
  • GNE $38.13
  • Revenue Growth
  • EOLS 17.15
  • GNE 3.75
  • 52 Week Low
  • EOLS $5.71
  • GNE $13.05
  • 52 Week High
  • EOLS $17.82
  • GNE $28.47
  • Technical
  • Relative Strength Index (RSI)
  • EOLS 44.82
  • GNE 47.57
  • Support Level
  • EOLS $6.08
  • GNE $14.70
  • Resistance Level
  • EOLS $6.36
  • GNE $15.28
  • Average True Range (ATR)
  • EOLS 0.22
  • GNE 0.51
  • MACD
  • EOLS 0.04
  • GNE 0.11
  • Stochastic Oscillator
  • EOLS 71.96
  • GNE 40.13

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

About GNE Genie Energy Ltd. Class B Stock

Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.

Share on Social Networks: